Last reviewed · How we verify
Neuroprotection — Competitive Intelligence Brief
phase 3
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
Neuroprotection (Neuroprotection) — The Central and Eastern European Gynecologic Oncology Group.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Neuroprotection TARGET | Neuroprotection | The Central and Eastern European Gynecologic Oncology Group | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Neuroprotection CI watch — RSS
- Neuroprotection CI watch — Atom
- Neuroprotection CI watch — JSON
- Neuroprotection alone — RSS
Cite this brief
Drug Landscape (2026). Neuroprotection — Competitive Intelligence Brief. https://druglandscape.com/ci/neuroprotection. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing